Westfield Capital Management Co. LP decreased its position in Acceleron Pharma Inc (NASDAQ:XLRN) by 11.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,220,161 shares of the biopharmaceutical company’s stock after selling 156,962 shares during the period. Westfield Capital Management Co. LP’s holdings in Acceleron Pharma were worth $50,124,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in Acceleron Pharma by 7.7% during the fourth quarter. Geode Capital Management LLC now owns 453,463 shares of the biopharmaceutical company’s stock worth $19,748,000 after acquiring an additional 32,521 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Acceleron Pharma by 1,068.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,151 shares of the biopharmaceutical company’s stock valued at $473,000 after purchasing an additional 9,282 shares in the last quarter. Quadrant Capital Group LLC acquired a new position in shares of Acceleron Pharma in the 1st quarter valued at approximately $46,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Acceleron Pharma by 13.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,958 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 356 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Acceleron Pharma by 10.8% in the 1st quarter. Rhumbline Advisers now owns 59,113 shares of the biopharmaceutical company’s stock valued at $2,753,000 after purchasing an additional 5,779 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Several analysts have commented on XLRN shares. ValuEngine upgraded shares of Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 8th. Morgan Stanley set a $53.00 price target on shares of Acceleron Pharma and gave the company a “hold” rating in a report on Monday, July 15th. HC Wainwright reissued a “buy” rating and set a $69.00 price objective on shares of Acceleron Pharma in a research report on Friday, September 6th. Zacks Investment Research reissued a “hold” rating on shares of Acceleron Pharma in a research report on Saturday, July 20th. Finally, Citigroup restated a “buy” rating and set a $66.00 price objective on shares of Acceleron Pharma in a report on Friday, May 24th. Six investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Acceleron Pharma presently has a consensus rating of “Buy” and a consensus target price of $60.10.

NASDAQ XLRN traded up $0.69 during trading on Wednesday, hitting $46.50. The stock had a trading volume of 15,863 shares, compared to its average volume of 214,929. Acceleron Pharma Inc has a 12 month low of $37.01 and a 12 month high of $59.59. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.11 and a current ratio of 17.11. The company’s 50-day moving average price is $44.26 and its two-hundred day moving average price is $42.87. The company has a market capitalization of $2.41 billion, a PE ratio of -17.92 and a beta of 1.23.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. The business had revenue of $27.67 million for the quarter, compared to the consensus estimate of $28.72 million. During the same period in the prior year, the business earned ($0.63) earnings per share. Acceleron Pharma’s revenue was up 649.9% compared to the same quarter last year. As a group, equities analysts anticipate that Acceleron Pharma Inc will post -2.33 earnings per share for the current fiscal year.

In other Acceleron Pharma news, CEO Habib J. Dable sold 5,625 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.23, for a total transaction of $254,418.75. Following the sale, the chief executive officer now directly owns 71,227 shares of the company’s stock, valued at approximately $3,221,597.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Adam M. Veness sold 824 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $45.20, for a total transaction of $37,244.80. Following the sale, the vice president now directly owns 16,124 shares in the company, valued at $728,804.80. The disclosure for this sale can be found here. In the last three months, insiders sold 88,416 shares of company stock worth $3,636,515. 2.50% of the stock is currently owned by insiders.

About Acceleron Pharma

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Featured Story: What is a short straddle?

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.